2. GPCR/G Protein Neuronal Signaling Apoptosis Autophagy Protein Tyrosine Kinase/RTK Stem Cell/Wnt MAPK/ERK Pathway PI3K/Akt/mTOR
  3. Dopamine Receptor Apoptosis Autophagy PDGFR ERK mTOR
  4. L 741742

L 741742 is a highly selective and brain-penetrant D4 dopamine receptor antagonist, with Ki values of 3.5 nM, 770 nM and >1700 nM for human D4, D3 and D2 receptors, respectively. L 741742 suppresses PDGFRβ, ERK1/2, and mTOR signaling pathways, and impairs autophagic flux while disrupting lysosomal function.L 741742 induces G0/G1 cell-cycle arrest and apoptosis, promotes neuronal differentiation of normal human neural stem cells, selectively inhibits growth and clonogenic potential of glioblastoma neural stem cells and primary glioblastoma tumor cells, exerts synergistic effects with Temozolomide (TMZ) (HY-17364) against glioblastoma neural stem cells in vitro, and inhibits glioblastoma neural stem cell xenograft growth in immunocompromised mice. L 741742 can be used for the research of schizophrenia and glioblastoma.

For research use only. We do not sell to patients.

L 741742

L 741742 Chemical Structure

CAS No. : 156337-32-5

Size Price Stock Quantity
5 mg In-stock
10 mg Get quote
25 mg Get quote
50 mg Get quote
100 mg Get quote
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of L 741742:

L 741742 Related Antibodies

Top Publications Citing Use of Products

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms
Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

L 741742 is a highly selective and brain-penetrant D4 dopamine receptor antagonist, with Ki values of 3.5 nM, 770 nM and >1700 nM for human D4, D3 and D2 receptors, respectively. L 741742 suppresses PDGFRβ, ERK1/2, and mTOR signaling pathways, and impairs autophagic flux while disrupting lysosomal function.L 741742 induces G0/G1 cell-cycle arrest and apoptosis, promotes neuronal differentiation of normal human neural stem cells, selectively inhibits growth and clonogenic potential of glioblastoma neural stem cells and primary glioblastoma tumor cells, exerts synergistic effects with Temozolomide (TMZ) (HY-17364) against glioblastoma neural stem cells in vitro, and inhibits glioblastoma neural stem cell xenograft growth in immunocompromised mice. L 741742 can be used for the research of schizophrenia and glioblastoma[1][2].

IC50 & Target[1]

Human D4 Receptor

3.5 nM (Ki)

Human D3 Receptor

770 nM (Ki)

Human D2 Receptor

>1500 nM (Ki)

In Vitro

L 741742 (compound 36) is a high-affinity, selective antagonist for hD4 receptors with a Ki of 3.5 nM, >500-fold selectivity over hD2 receptors, and >200-fold selectivity over hD3 receptors[1].
L 741742 (1.5-6.2 μM; 5 days) selectively inhibits the growth of patient-derived glioblastoma neural stem cells (GNS) with an IC50 of 1.5-6.2 μM and shows minimal activity against non-neural stem cell lines[2].
L 741742 (10 μM; 14 days) potently reduces the clonogenic potential of freshly isolated patient-derived glioblastoma tumor cells by 40- to 83-fold[3].
L 741742 (3 weeks) promotes neuronal differentiation of normal human neural stem cells, as indicated by increased VGlut1 expression[2].
L 741742 (10 μM; 48 hr) induces massive accumulation of autophagosomes in G411 and G362 glioblastoma neural stem cells, as shown by increased LC3B-II levels and LC3B+ puncta[2].
L 741742 (10 μM; 48 hr) impairs autophagic flux in G411 glioblastoma neural stem cells, as indicated by blocked LC3B-II turnover in the presence of Chloroquine (HY-17589A)[2].
L 741742 (10 μM) inhibits the PDGFRβ-ERK1/2 and mTOR signaling pathways in glioblastoma neural stem cells, as shown by reduced phosphorylation of ERK1/2, PDGFRβ, and S6[2].
L 741742 (10 μM; 48 hr) induces G0/G1 cell cycle arrest and subsequent apoptosis in G411 and G362 glioblastoma neural stem cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

L 741742 Related Antibodies

Cell Autophagy Assay[2]

Cell Line: GNS lines (G411, G362)
Concentration: 10 μM
Incubation Time: 2 hr; 24 hr; 48 hr
Result: Increased LC3B-II levels (a marker of autophagosome formation) at 48 hr.
Induced LC3B+ puncta in >50% of cells at 48 hr, with a significant increase in the percentage of LC3B+ cells compared with controls.

Cell Autophagy Assay[2]

Cell Line: G411 GNS cells
Concentration: 10 μM
Incubation Time: 48 hr
Result: Increased LC3B-II levels when administered alone, but did not increase LC3B-II levels in the presence of chloroquine, confirming impaired autophagic flux.

Western Blot Analysis[2]

Cell Line: GNS lines (G362, G411), normal NS, fibroblasts
Concentration: 10 μM
Incubation Time: 2 hr; 24 hr; 48 hr
Result: Decreased phosphorylation of ERK1/2 over time in GNS (but not in NS or fibroblasts).
Decreased phosphorylation of PDGFRβ at 48 hr.
Decreased phosphorylation of S6 (a downstream mTOR effector) at 48 hr.

Cell Cycle Analysis[2]

Cell Line: GNS lines (G411, G362)
Concentration: 10 μM
Incubation Time: 48 hr
Result: Induced G0/G1 phase arrest, with G411 cells showing a shift from 74.7% G1 (control) to 92.2% G1.
Increased caspase 3/7 activity.
Induced cleaved PARP expression at 48 hr.
Parmacokinetics
Species Dose Route F T1/2
Rat[2] 3 mg/kg p.o. 38 % 2 h
In Vivo

L 741742 (20 mg/kg; i.p.; 5 days on, 2 days off) significantly inhibits subcutaneous glioblastoma xenograft growth by 40.9% and reduces tumor stem cell frequency in NSG mice[2].
L 741742 (25 mg/kg; i.p.; 5 days on, 2 days off; 2 weeks) provides a significant survival benefit in mice with intracranial glioblastoma xenografts[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD scid gamma (NSG) (female)[2]
Dosage: 20 mg/kg
Administration: i.p.; 5 days on, 2 days off; until study endpoint
Result: Reduced endpoint tumor volumes.
Reduced average tumor weight by 40.9% relative to controls.
Reduced the frequency of sphere-forming (stem-like) cells to 1 in 75.6.
Increased levels of p62, ubiquitinated protein conjugates, and LC3-positive cells, confirming impaired autophagic flux in vivo.
Molecular Weight

380.91

Formula

C23H25ClN2O
CAS No.
Appearance

Solid

SMILES

CC1=C(C2=CC=C(Cl)C=C2)ON=C1C3CCN(CCC4=CC=CC=C4)CC3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 20 mg/mL (52.51 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6253 mL 13.1265 mL 26.2529 mL
5 mM 0.5251 mL 2.6253 mL 5.2506 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2 mg/mL (5.25 mM); Suspended solution

    This protocol yields a suspended solution of ≥ 2 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2 mg/mL (5.25 mM); Suspended solution

    This protocol yields a suspended solution of ≥ 2 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.6253 mL 13.1265 mL 26.2529 mL 65.6323 mL
5 mM 0.5251 mL 2.6253 mL 5.2506 mL 13.1265 mL
10 mM 0.2625 mL 1.3126 mL 2.6253 mL 6.5632 mL
15 mM 0.1750 mL 0.8751 mL 1.7502 mL 4.3755 mL
20 mM 0.1313 mL 0.6563 mL 1.3126 mL 3.2816 mL
25 mM 0.1050 mL 0.5251 mL 1.0501 mL 2.6253 mL
30 mM 0.0875 mL 0.4375 mL 0.8751 mL 2.1877 mL
40 mM 0.0656 mL 0.3282 mL 0.6563 mL 1.6408 mL
50 mM 0.0525 mL 0.2625 mL 0.5251 mL 1.3126 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

L 741742 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

L 741742156337-32-5L741742L-741742Dopamine ReceptorApoptosisAutophagyPDGFRERKmTORPlatelet-derived growth factor receptorExtracellular signal regulated kinasesMammalian target of Rapamycindopamine D4 receptorERK1/25HT1A receptorsglioblastoma neural stem cellshuman dopamine D4 receptor-expressing cellsschizophrenia5HT2 receptorsmTOR signaling pathwaysprimary glioblastoma tumor cellsPDGFRβInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
L 741742
Cat. No.:
HY-101349
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.